Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system in gp120-mediated insults and HIV-associated dementia.
Exp Neurol 2010; 224(1):74-84EN

Abstract

Endocannabinoids (eCBs) include a group of lipid mediators that act as endogenous agonists at cannabinoid (CB(1), CB(2)) and vanilloid (TRPV1) receptors. In the last two decades a number of eCBs-metabolizing enzymes have been discovered that, together with eCBs and congeners, target receptors and proteins responsible for their transport and intracellular trafficking form the so-called "endocannabinoid system" (ECS). Within the central nervous system ECS elements participate in neuroprotection against neuroinflammatory/neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. More recently, a role for eCBs has been documented also in human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120-mediated insults, and in HIV-associated dementia (HAD). The modulation of ECS in the latter disease conditions is the subject of this review, that will also address the molecular mechanisms underlying the neuroprotective effects of eCBs. In particular, the interactions between neurons and glia during neuroinflammation, and the alterations of ECS in these cells upon gp120 insults and HAD will be discussed, along with the potential therapeutic exploitation of ECS-oriented drugs for the treatment of HAD and related disorders.

Authors+Show Affiliations

Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20353779

Citation

Bari, Monica, et al. "The Endocannabinoid System in Gp120-mediated Insults and HIV-associated Dementia." Experimental Neurology, vol. 224, no. 1, 2010, pp. 74-84.
Bari M, Rapino C, Mozetic P, et al. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. Exp Neurol. 2010;224(1):74-84.
Bari, M., Rapino, C., Mozetic, P., & Maccarrone, M. (2010). The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. Experimental Neurology, 224(1), pp. 74-84. doi:10.1016/j.expneurol.2010.03.025.
Bari M, et al. The Endocannabinoid System in Gp120-mediated Insults and HIV-associated Dementia. Exp Neurol. 2010;224(1):74-84. PubMed PMID: 20353779.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. AU - Bari,Monica, AU - Rapino,Cinzia, AU - Mozetic,Pamela, AU - Maccarrone,Mauro, Y1 - 2010/03/29/ PY - 2010/4/1/entrez PY - 2010/4/1/pubmed PY - 2010/6/29/medline SP - 74 EP - 84 JF - Experimental neurology JO - Exp. Neurol. VL - 224 IS - 1 N2 - Endocannabinoids (eCBs) include a group of lipid mediators that act as endogenous agonists at cannabinoid (CB(1), CB(2)) and vanilloid (TRPV1) receptors. In the last two decades a number of eCBs-metabolizing enzymes have been discovered that, together with eCBs and congeners, target receptors and proteins responsible for their transport and intracellular trafficking form the so-called "endocannabinoid system" (ECS). Within the central nervous system ECS elements participate in neuroprotection against neuroinflammatory/neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. More recently, a role for eCBs has been documented also in human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120-mediated insults, and in HIV-associated dementia (HAD). The modulation of ECS in the latter disease conditions is the subject of this review, that will also address the molecular mechanisms underlying the neuroprotective effects of eCBs. In particular, the interactions between neurons and glia during neuroinflammation, and the alterations of ECS in these cells upon gp120 insults and HAD will be discussed, along with the potential therapeutic exploitation of ECS-oriented drugs for the treatment of HAD and related disorders. SN - 1090-2430 UR - https://www.unboundmedicine.com/medline/citation/20353779/The_endocannabinoid_system_in_gp120_mediated_insults_and_HIV_associated_dementia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-4886(10)00110-X DB - PRIME DP - Unbound Medicine ER -